Ondexxya
E852345
Ondexxya is the brand name of andexanet alfa, a reversal agent used to counteract the anticoagulant effects of factor Xa inhibitors in cases of life-threatening or uncontrolled bleeding.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ondexxya canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10291905 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ondexxya Context triple: [andexanet alfa, hasTradeName, Ondexxya]
-
A.
Arlanxeo
Arlanxeo is a global synthetic rubber company specializing in high-performance elastomer products for the automotive, construction, and industrial sectors.
-
B.
Xyloskalo
Xyloskalo is a mountain pass and popular trailhead on Crete that serves as the main entrance to the Samaria Gorge hiking route.
-
C.
Nobatia
Nobatia was an early medieval Nubian kingdom in Lower Nubia that emerged after the decline of Meroë and later became part of the Christian Nubian state of Makuria.
-
D.
Garrodia
Garrodia is a genus of small seabirds known as storm petrels within the family Hydrobatidae.
-
E.
Shimea
Shimea is a biblical figure mentioned in the Hebrew Bible as one of King David’s brothers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ondexxya Target entity description: Ondexxya is the brand name of andexanet alfa, a reversal agent used to counteract the anticoagulant effects of factor Xa inhibitors in cases of life-threatening or uncontrolled bleeding.
-
A.
Arlanxeo
Arlanxeo is a global synthetic rubber company specializing in high-performance elastomer products for the automotive, construction, and industrial sectors.
-
B.
Xyloskalo
Xyloskalo is a mountain pass and popular trailhead on Crete that serves as the main entrance to the Samaria Gorge hiking route.
-
C.
Nobatia
Nobatia was an early medieval Nubian kingdom in Lower Nubia that emerged after the decline of Meroë and later became part of the Christian Nubian state of Makuria.
-
D.
Garrodia
Garrodia is a genus of small seabirds known as storm petrels within the family Hydrobatidae.
-
E.
Shimea
Shimea is a biblical figure mentioned in the Hebrew Bible as one of King David’s brothers.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
andexanet alfa
ⓘ
brand name drug ⓘ |
| affectsBiologicalProcess | blood coagulation ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToRegulatoryProgram | Risk Evaluation and Mitigation Strategy in the United States ⓘ |
| developedBy |
Alexion Pharmaceuticals
NERFINISHED
ⓘ
Portola Pharmaceuticals NERFINISHED ⓘ |
| doesNotReverse |
heparin
ⓘ
low molecular weight heparin ⓘ vitamin K antagonists ⓘ |
| hasActiveIngredient | andexanet alfa NERFINISHED ⓘ |
| hasApprovalYear | 2018 ⓘ |
| hasATCCode | V03AB38 ⓘ |
| hasBlackBoxWarning |
cardiac arrest
ⓘ
ischemic events ⓘ sudden death ⓘ thromboembolic risk ⓘ |
| hasCommonAdverseEffect |
pneumonia
ⓘ
thromboembolic events ⓘ urinary tract infection ⓘ |
| hasContraindication | known hypersensitivity to andexanet alfa ⓘ |
| hasHalfLife | approximately 1 hour ⓘ |
| hasIndication |
reversal of anticoagulant effects of factor Xa inhibitors
ⓘ
treatment of life-threatening bleeding in patients on factor Xa inhibitors ⓘ treatment of uncontrolled bleeding in patients on factor Xa inhibitors ⓘ |
| hasINN | andexanet alfa NERFINISHED ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
acts as a decoy factor Xa protein
ⓘ
binds and sequesters factor Xa inhibitors ⓘ reverses anticoagulant activity of factor Xa inhibitors ⓘ |
| hasMolecularTarget | factor Xa inhibitors bound to factor Xa ⓘ |
| hasOnsetOfAction | within minutes of infusion ⓘ |
| hasPharmaceuticalForm | powder for concentrate for solution for infusion ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| hasTradeName | Ondexxya NERFINISHED ⓘ |
| isAdministeredAs | intravenous bolus followed by infusion ⓘ |
| isUsedBySpecialty |
cardiology
ⓘ
emergency medicine ⓘ hematology ⓘ |
| isUsedIn | hospitals ⓘ |
| marketedBy | Alexion Pharmaceuticals NERFINISHED ⓘ |
| requiresMonitoring |
return of bleeding
ⓘ
signs and symptoms of thrombosis ⓘ |
| targetsDrug |
apixaban
NERFINISHED
ⓘ
rivaroxaban NERFINISHED ⓘ |
| targetsDrugClass | direct factor Xa inhibitors ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ondexxya Description of subject: Ondexxya is the brand name of andexanet alfa, a reversal agent used to counteract the anticoagulant effects of factor Xa inhibitors in cases of life-threatening or uncontrolled bleeding.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.